NIH awards WSU researcher $1.7 million to study non-alcoholic fatty liver disease
July 28, 2011
DETROIT - Kezhong Zhang, Ph.D., assistant professor of molecular medicine and genetics and of immunology and microbiology in the School of Medicine at Wayne State University, was awarded $1.7 million by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health to explore how molecular elements in the body regulate the development of non-alcoholic fatty liver disease (NAFLD).
Zhang aims to identify the mechanism that regulates CREBH (cyclic AMP-responsive element-binding protein H), a transcription factor he believes is closely associated with the progression of NAFLD. Transcription factors are molecules that either promote or block the body from interpreting the DNA codes that tell the body what kind of proteins it needs to produce.
"Recently, we have accumulated strong preliminary evidence that CREBH plays a crucial role in regulating hepatic lipid homeostasis under metabolic stress conditions," Zhang said. In a previous study, Zhang and his colleagues found that when they removed CREBH from the animal body, the accumulation of fat was reduced in the liver but increased in the blood stream.
Zhang hypothesizes that an excess of saturated fatty acids or inflammatory stimuli activates CREBH to facilitate fat production and digestion. Because fat contents are stuck in the liver, CREBH activity is crucial for the excessive fat buildup that characterizes and propagates NAFLD.
"This project will not only define the molecular basis by which a novel stress-sensing protein factor regulates lipid metabolism, it will also be significant for designing new strategies to prevent and treat human non-alcoholic fatty liver disease and its associated metabolic syndromes," said Zhang.
The first step in Zhang's investigation is to identify the mechanism that causes fatty acids to activate CREBH. He will then decipher the molecular code that allows CREBH to control the amount of fatty acids in the liver. His final step will be to understand the involvement of CREBH in taking fatty liver disease to its more severe state, steatohepatitis.
Zhang is collaborating with School of Medicine colleagues Leonard Lipovich, Ph.D., assistant professor of molecular medicine and genetics and of and neurology; Todd Leff, Ph.D., associate professor of pathology; Bruce Berkowitz, Ph.D., professor of anatomy and director of WSU's Small Animal MRI Facility. Zhang is also working with Stephen Duncan, D.Phil., Marcus Professor of Human and Molecular Genetics at the Medical College of Wisconsin; and Maria Isabel Fiel, M.D., professor of pathology at the Mount Sinai School of Medicine in New York City.
Wayne State University is one of the nation's pre-eminent public research universities in an urban setting. Through its multidisciplinary approach to research and education, and its ongoing collaboration with government, industry and other institutions, the university seeks to enhance economic growth and improve the quality of life in the city of Detroit, state of Michigan and throughout the world. For more information about research at Wayne State University, visit http://www.research.wayne.edu.
Contact: Julie O'Connor
Phone: (313) 577-8845